Table 1:

Health care and combined oral contraceptive use at baseline

CharacteristicPolycystic ovary syndrome*Matched controls
Women, no.43 50643 506
Age, yr, mean28.728.9
Health care use, % of women
Admission to hospital3.574.05
Emergency department visit4.794.45
Physician office visit51.3150.08
Combined oral contraceptive use
New user, no. (%) of women20 150 (46.32)20 278 (46.61)
Prevalent user, no. (%) of women23 356 (53.68)23 228 (53.39)
Prior time on combined oral contraceptives, mean, d103103
Total time on combined oral contraceptives, mean, d201202
Number of combined oral contraceptives products used in the past, mean0.60.6
Combined oral contraceptive, % of women
Desogestrel, μg ethinyl estradiol
Drospirenone, μg ethinyl estradiol
Levonorgestrel, μg ethinyl estradiol
Norethindrone, μg ethinyl estradiol
Norethindrone acetate, μg ethinyl estradiol
Norgestimate, ethinyl-estradiol μg
Norgestrel, μg ethinyl estradiol
  • * Defined as a claim for polycystic ovary syndrome (International Classification of Disease, 9th Revision [Clinical Modification (ICD-9-CM)] 256.4).

  • Initiated combined oral contraceptive therapy after the polycystic ovary syndrome claim.

  • Evidence of combined oral contraceptive use during the 365-day period before the polycystic ovary syndrome claim.